<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246190</url>
  </required_header>
  <id_info>
    <org_study_id>A65_03BE1921</org_study_id>
    <nct_id>NCT04246190</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the&#xD;
      Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of&#xD;
      CKD-501 and D759 in Healthy Adults&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 24, 2020</start_date>
  <completion_date type="Anticipated">July 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-501, D759 and CKD-396</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum plasma concentration of CKD-501, D759 and CKD-396</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-501, D759 and CKD-396</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of CKD-501, D759 and CKD-396</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501 and D759&#xD;
Period 2: CKD-396</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-396&#xD;
Period 2: CKD-501 and D759</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 and D759</intervention_name>
    <description>Reference drug, CKD-501 1T and D759 1T, QD, PO</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-396</intervention_name>
    <description>Reference drug, CKD-396 1T, QD, PO</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult who is 19 ~ 55 years at the time of screening&#xD;
&#xD;
          2. Body weight more than 55 kg for male and more than 50kg for female&#xD;
&#xD;
          3. BMI more than 18.5 kg/m2 or less than 27.0 kg/m2&#xD;
&#xD;
          4. Females must be menopause or surgical infertility&#xD;
&#xD;
          5. Males who have consented to the use of appropriate pregnancy contraceptive methods up&#xD;
             to 28 days after the last investigational product and not to provide sperm&#xD;
&#xD;
          6. Subjects who voluntarily decided to participate and informed consent based upon&#xD;
             understanding on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a history of clinically significant hepatic, renal, nervous, immune,&#xD;
             respiratory, urinary, digestion, endocrine, hematooncology, cardiovascular systemic&#xD;
             disease or psychosis disorder&#xD;
&#xD;
          2. Subjects who have diabetic ketoacidoisis, diabetic coma, diabetic precoma, Type 1&#xD;
             diabetes&#xD;
&#xD;
          3. Subjects who have genetic problems such as galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          4. Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative&#xD;
             colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may&#xD;
             affect the absorption of the drug&#xD;
&#xD;
          5. Subjects who have a history of clinically significant hypersensitivity to drugs or&#xD;
             additives, including components of the investigational product(lobeglitazone,&#xD;
             sitagliptin) and same class drug with thiazolidinediones&#xD;
&#xD;
          6. Subjects who have severe infectious disease and severe trauma before and after&#xD;
             operation&#xD;
&#xD;
          7. Subjects who are deemed unsuitable as subjects in the screening test performed within&#xD;
             28 days before the administration of investigational product&#xD;
&#xD;
               -  AST, ALT&gt; UNL(Upper Normal Limit)x1.25&#xD;
&#xD;
               -  Total bilirubin &gt; UNL(Upper Normal Limit)x1.5&#xD;
&#xD;
               -  eGFR (Estimated Glomerular Filtration Rate) &lt;60 mL/min/1.73m2 using the MDRD&#xD;
                  (Modification of Diet in Renal Disease) formula&#xD;
&#xD;
               -  Positive immunologic serological tests (hepatitis B test, hepatitis C test, human&#xD;
                  immunodeficiency virus (HIV) test, syphilis test)&#xD;
&#xD;
               -  After resting for more than 5 minutes, systolic blood pressure&gt; 150 mmHg or &lt; 90&#xD;
                  mmHg, diastolic blood pressure&gt; 100 mmHg or &lt;50 mmHg&#xD;
&#xD;
          8. Subjects who have had a history of drug abuse within one year of screening or have&#xD;
             tested positive on urine drug screening test&#xD;
&#xD;
          9. Pregnant or lactating women&#xD;
&#xD;
         10. Subjects who have consistently excessively smoked or consumed caffeine or alcohol&#xD;
             (caffeine:&gt; 5 cups / day, alcohol:&gt; 210 g / week, cigarettes:&gt; 10 cigarettes / day) or&#xD;
             cannot stop smoking, consuming caffeine and alcohol during hospitalization&#xD;
&#xD;
         11. Subjects who judged to able to affect in the study or in the subject's safety by the&#xD;
             investigator for the following reasons&#xD;
&#xD;
               -  Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first&#xD;
                  administration of the investigational drug.&#xD;
&#xD;
               -  Over-the-counter (OTC) drugs, including health foods and vitamin preparations,&#xD;
                  within 7 days of the first dose of the investigational product&#xD;
&#xD;
         12. Subjects who have received the investigational product by participating in other&#xD;
             clinical trials (including bioequivalence studies) within 180 days before the first&#xD;
             dose of the investigational product (For biological agents, this may be based on a&#xD;
             longer period of time, considering the half-life)&#xD;
&#xD;
         13. Subjects who donated whole blood within 60 days before the first dose of the&#xD;
             investigational product or donated component blood donation within 30 days&#xD;
&#xD;
         14. Subjects who received a blood transfusion within 60 days before the first dose of the&#xD;
             investigational product&#xD;
&#xD;
         15. Subjects who were deemed to be inappropriate to participate in the study by the&#xD;
             investigator judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D. M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Soo Park, Ph.D. M.D</last_name>
    <phone>+82-2-2228-0401</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Soo Park, Ph.D. M.D</last_name>
      <phone>+82-2-2228-0401</phone>
      <email>minspark@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Min Soo Park, Ph.D. M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

